Beyond the lab: three women turning European deep tech into market-ready solutions
Brussels, October 19th 2026
Summary
›Three EIC-backed women founders are advancing deep-tech solutions from hydrogen production to early cancer detection and non-invasive diagnostics.
›HyCarb is commercialising an intermediate-temperature catalytic methane splitting process to produce hydrogen and graphitic carbon and is advancing toward TRL 6.
›CheMOnitor combines molecular analysis and AI to predict chemotherapy effectiveness after a first dose but faces clinical validation and regulatory hurdles.
›D-Tails is developing yeast-based biosensors and synthetic olfaction for urine-based cancer screening with EIC Pathfinder support.
›The EIC Women Leadership Programme supports leadership and market-readiness but early-stage claims require careful scrutiny around validation, regulation and scalability.
Beyond the lab: three women turning European deep tech into market-ready solutions
Europe’s deep-tech pipeline increasingly depends on researchers who can navigate both laboratory complexity and the commercial system. This article profiles three women innovators supported by European programmes who are pushing technologies toward real‑world use. Their projects span energy and healthcare and illustrate typical deep‑tech trajectories from invention to validation and commercialisation. The profiles also highlight the recurring challenges that tend to be underplayed in promotional accounts including scale-up risks, regulatory pathways, market adoption barriers and the need for sustained quality systems.
Profiles
Paula Dias — Co‑founder, HyCarb (Porto, Portugal):Paula Dias co‑founded HyCarb in 2024 as a spin‑off from the Faculty of Engineering of the University of Porto. A chemical engineer and materials researcher, she is co‑inventor of a patented intermediate‑temperature catalytic methane splitting process (branded IT‑CMS) and coordinator of the EIC Transition‑supported ZeroCarb project. HyCarb’s core claim is a process that produces clean hydrogen plus high‑value graphitic carbon rather than emitting CO2. The company is working to validate the technology at TRL 6 and to position itself for industrial deployment and commercialisation.
HyCarb has also signalled attention to operational quality. In April 2026 the company announced the start of an ISO 9001 certification process. ISO 9001 is a quality management standard that can help early scale‑ups formalise processes required by industrial customers. The company’s stated combination of hydrogen and graphitic carbon offers a co‑product revenue route that can alter project economics when compared with single‑product hydrogen plants.
Why the process matters and what to watch for:Catalytic methane splitting converts methane into hydrogen and solid carbon rather than CO2. The appeal is lower direct CO2 emissions compared with steam methane reforming. Yet the net climate benefit depends on feedstock methane leakage, the energy source for the process, and how the solid carbon is valued and used. Key commercial hurdles include scaling catalyst life and stability, handling and selling graphitic carbon reliably, capital intensity relative to electrolytic green hydrogen, and achieving competitive levelised cost of hydrogen.
Paula’s role and milestones:Dias leads project management, partner coordination and dissemination for ZeroCarb and supports validation, market intelligence and strategic positioning. The project’s explicit goal is reaching TRL 6 which means demonstration of a system prototype in an operational environment. That is an important but costly milestone that typically precedes detailed engineering, permitting and customer pilots.
Critical perspective:The technology proposition is promising but early. Methane splitting competes with increasingly cheap electrolytic hydrogen when low‑carbon electricity is abundant. Claims about affordability and sustainability must be tied to lifecycle greenhouse gas accounting and transparent cost models. ISO 9001 and TRL progress are positive signals but not guarantees of market uptake.
Rebeka Török — CEO, CheMOnitor (Budapest, Hungary):Rebeka Török is the CEO and co‑founder of CheMOnitor, a venture originating from basic research at the University of Pannonia. The company is developing an early diagnostic solution designed to predict the effectiveness of chemotherapy for lung cancer patients after the first dose. CheMOnitor combines advanced molecular analysis with artificial intelligence to generate a predictive read‑out that could shorten the time clinicians need to decide whether to continue a regimen or change course.
CheMOnitor participated in the EIT Jumpstarter 2025 Healthcare programme and won third place in the health category. The team advertises investment opportunities starting from around €1.2 million. The company is positioning itself as a clinical decision support tool that could reduce patient exposure to ineffective therapies and accelerate personalised care.
Technical and regulatory considerations:Predictive diagnostics that pair molecular markers and machine learning can be powerful but demand rigorous clinical validation. For a tool that influences treatment decisions the pathway includes analytical validation, clinical validation in prospective cohorts and regulatory approval under medical device rules such as CE marking in Europe and possibly Notified Body review. AI‑based models also need transparency, external validation across diverse patient populations, and governance for model drift and updates. Reimbursement and integration into oncology workflows are additional barriers.
Rebeka’s role and milestones:Török leads business development, market strategy and the translation of the PhD‑level research into a commercial product. Securing clinical partners and investor support are immediate priorities. The EIT Jumpstarter result suggests early commercial traction but is only an early milestone in a long, evidence‑driven market access journey.
Critical perspective:Early programme prizes and incubator successes are encouraging signals but not proof of clinical benefit. Clinicians and payers will require peer‑reviewed evidence from prospective studies and clear pathways for regulatory clearance and reimbursement. The company must also address data privacy, explainability of AI outputs and prospective validation in varied clinical settings.
Viola Folli — Co‑founder and CSO, D‑Tails (Rome, Italy):Viola Folli co‑founded D‑Tails in 2021. The company develops biosensors and synthetic olfaction technologies for non‑invasive cancer detection, focusing on urine‑based assays. D‑Tails combines synthetic biology, microfluidics and AI to detect molecular signatures associated with cancers. Folli coordinates the EIC Pathfinder‑funded ULYSSES project which targets yeast‑based biosensors for breast and prostate cancer detection and aims to translate research into an accessible diagnostic platform.
How synthetic olfaction and yeast biosensors work in this context:Synthetic olfaction mimics biological smell detection by sensing volatile or soluble biomarkers and applying pattern recognition to classify signals. Yeast or other engineered cells can be programmed to respond to specific molecules and produce measurable outputs. Combining these living sensors with microfluidic sample handling and AI analysis can create compact tests. However, biology introduces variability and sensor stability, and urine is a complex matrix that requires robust sample preparation and controls.
Viola’s role and milestones:Folli leads scientific strategy, coordinates international partners and steers the biosensor development within ULYSSES. The project aims to provide a non‑invasive screening tool that could make early detection more accessible and lower costs compared with liquid biopsies or imaging. Translating lab prototypes to clinical screening devices requires reproducible manufacturing, regulatory classification, and demonstration of population‑level performance.
Critical perspective:Non‑invasive screening technologies attract attention because of potential scale. Yet demonstrating sensitivity and specificity that outperform or complement existing screening modalities is difficult. False positives can create downstream costs and patient harm. The synthetic biology components also raise questions about stability, storage, shelf life, and regulatory classification under in vitro diagnostic rules.
Comparative snapshot
Company
Core technology
EIC or programme support
Headquarters
Stage / TRL or equivalent
Near‑term milestones
Key risks
HyCarb
Intermediate‑temperature catalytic methane splitting producing H2 and graphitic carbon
EIC Transition (ZeroCarb); spin‑off from University of Porto; ISO 9001 process started
Porto, Portugal
Targeting TRL 6
Demonstrate pilot in operational environment; validate catalyst life and carbon product streams
Lifecycle emissions, methane leakage, catalyst durability, CAPEX and market for graphitic carbon
CheMOnitor
Molecular analysis plus AI to predict chemotherapy response after first dose
EIT Jumpstarter 2025 Healthcare finalist; originating from University of Pannonia
Budapest, Hungary
Early clinical development; pre‑market
Secure clinical partnerships for prospective validation; secure seed or series A funding
Clinical validation, regulatory approval, AI explainability and reimbursement
D‑Tails
Yeast‑based biosensors and synthetic olfaction for urine‑based cancer screening
EIC Pathfinder (ULYSSES); founded 2021
Rome, Italy
Research to preclinical prototype
Advance biosensor robustness and pilot studies for breast and prostate cancer detection
Analytical specificity/sensitivity, biological stability, scaling manufacturing and regulatory pathway
What the EIC Women Leadership Programme contributes
The EIC Women Leadership Programme is positioned as a skills and network accelerator that runs cohorts of researchers and entrepreneurs through combined mentoring, coaching and training. The programme aims to improve negotiation, pitching and leadership skills and to increase visibility for women innovators within the EIC ecosystem. Since its pilot launch in 2021 the programme reports nine cohorts and more than 300 participants from the EIC and EIT communities.
Reported impact and broader EIC context:The EIC highlights progress on gender representation across its instruments. In 2024, 30 percent of companies supported in the EIC Accelerator were women led and the overall Accelerator portfolio included 134 women‑led companies or about 19 percent. Coordination rates for women in Pathfinder and Transition projects were 24 percent and 23 percent respectively. The EIC also points to other interventions such as Women TechEU and the European Prize for Women Innovators.
Critical perspective on programmes and metrics:Leadership training and networking are necessary components for improving representation but they do not by themselves remove structural barriers. Access to follow‑on capital, procurement pipelines and corporate partnerships matter more for scaling. Reported percentages are positive but still reflect a gender gap across high‑growth deep tech. Measuring long‑term outcomes requires tracking follow‑on funding, market entry, job creation and survival rates over multiple years.
Paths to market and common hurdles
Across hydrogen and healthcare deep tech there are recurring bottlenecks that shape how promising laboratory results translate into commercial impact. Those include technical scale‑up, verification in operational settings, regulatory approval especially in medical devices and diagnostics, industrial standards and quality management, capital intensity for pilot plants, customer procurement cycles and evidence requirements demanded by payers and buyers.
Technology readiness and commercialisation:Technology Readiness Levels are shorthand for stages in development. Moving from TRL 4 or 5 to TRL 6 and beyond typically requires significant engineering, increased funding and engagement with industrial partners. Reaching TRL 8 or 9 involves proving the solution in operational conditions and establishing manufacturing and supply chains.
Regulation, evidence and procurement:For diagnostics and clinical decision tools the route includes analytical validation, clinical trials and regulatory classification under in vitro diagnostic and medical device frameworks. For energy technologies, safety, environmental permits and standardisation matter. Public procurement programmes can be an accelerant but they require suppliers to meet compliance and liability standards. The EIC Business Acceleration Services provide matchmaking, coaching and procurement access but companies still need to translate pilot projects into repeatable contracts.
What this means for the European deep‑tech ecosystem
The three profiles show the complementary roles of research institutions, EU support programmes and entrepreneurial teams in advancing deep tech. European funding and acceleration services fill an essential gap between science and industry. Still, the transition from demonstration to commercial scaling depends on realistic cost models, independent validation, regulatory compliance and long term capital. Storytelling around innovation is valuable to build networks and attract partners yet it risks overselling early achievements when milestones remain to be delivered.
Practical signals investors, customers and policymakers should look for include detailed lifecycle assessments for energy technologies, prospective clinical studies for diagnostics, clear quality management plans such as ISO adoption, demonstrable pilot customers or procurement commitments, and credible capital deployment plans aligned to the scale of technical risk.
Practical next steps for each company
HyCarb should prioritise independent lifecycle greenhouse gas accounting, demonstrate catalyst lifetime at scale and secure buyers for both hydrogen and graphitic carbon. CheMOnitor needs prospective clinical validation, external AI model audits and a regulatory pathway to CE marking. D‑Tails must show reproducible biosensor performance across clinical samples, resolve stability and manufacturing questions and engage with diagnostic regulators early.
Acknowledgement and how to follow up
These profiles are based on publicly available EIC and partner material, company announcements and programme descriptions. For follow up, readers can consult the EIC Community platform for open calls, the EIC Business Acceleration Services for support offers and the EIC Women Leadership Programme for cohort details. Interested investors or partners should request technical dossiers, validation data and regulatory roadmaps from the companies before making commitments.
Key terms explained
Technology Readiness Level (TRL):TRLs are a 1 to 9 scale used to indicate maturity. TRL 6 generally means a system prototype has been demonstrated in a relevant environment. TRL 9 is a system proven in an operational environment. Many deep‑tech companies stall between TRL 6 and commercial scale due to cost and integration issues.
Intermediate‑temperature catalytic methane splitting (IT‑CMS):A thermochemical route that breaks methane into hydrogen and solid carbon using a catalyst at temperatures lower than conventional pyrolysis. The process aims to avoid CO2 emissions associated with steam methane reforming but must be assessed across the full supply chain for methane leaks and energy inputs.
Synthetic olfaction and biosensors:Synthetic olfaction uses sensor arrays and pattern recognition to detect complex chemical signatures. Engineered biosensors use living cells or biomolecules to produce signal outputs when they encounter target analytes. Both approaches require rigorous calibration, stability controls and robust data analysis to be clinically useful.
Final note
The three women and their companies illustrate both what European support programmes can enable and the distance that often remains between lab demonstrations and reliable, scaled products. The EIC ecosystem provides important scaffolding for leadership development, technical validation and market access. Real world impact will be determined by evidence, regulation, manufacturing readiness and the ability to secure downstream contracts and funding.